Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques

Jessica Radzio, Krisztina Hanley, James Mitchell, Shanon Ellis, Frank Deyounks, Leecresia Jenkins, Walid Heneine, J. Gerardo García-Lerma

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Concerns that the injectable contraceptive depotmedroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume67
Issue number4
DOIs
StatePublished - 2014

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques'. Together they form a unique fingerprint.

Cite this